Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Using pharmacogenetics to predict methotrexate response in rheumatoid arthritis patients.

Expert opinion on drug metabolism & toxicology - 1 Jul 2020

Szostak Bartosz, Machaj Filip, Rosik Jakub, Pawlik Andrzej

Abstract excerpt

INTRODUCTION: Methotrexate (MTX) is a folate antagonist and a first-line drug for the treatment of rheumatoid arthritis (RA). However, in up to 30% of cases, MTX monotherapy is insufficient, while a further 30% of patients suffer with severe adverse effects. Despite extensive clinical evidence, it is not currently possible to predict therapy outcomes and drug toxicity for MTX. Therefore, to establish biomarkers...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antirheumatic Agents
Share to Arthritis, Rheumatoid

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Biomarkers

Share to Genome-Wide Association Study

Share to Methotrexate

Share to Pharmacogenetics

Share to Precision Medicine

Share to Treatment Outcome

Source

Identifiers

PMID: 32500745
DOI: 10.1080/17425255.2020.1777279

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Using pharmacogenetics to predict methotrexate response in rheumatoid arthritis patients.PMID 32500745Read ↗

Methotrexate pharmacogenetics in rheumatoid arthritis: a status report.Semantic proximity Read ↗

Methotrexate Pharmacogenetics in the Treatment of Rheumatoid ArthritisSemantic proximity Read ↗

The pharmacogenetics of methotrexateSemantic proximity Read ↗

Effect of Genetic Polymorphisms in the Folate Pathway on Methotrexate Therapy in Rheumatic DiseasesSemantic proximity Read ↗

Genetic polymorphisms associated with therapeutic response and adverse effects to methotrexate in Taiwanese patients with rheumatoid arthritis: a real-world, hospital-based study.Semantic proximity Read ↗

Polymorphisms in Methotrexate Pathways: What Is Clinically Relevant, What Is Not, and What Is PromisingSemantic proximity Read ↗

Evaluation of a clinical pharmacogenetics model to predict methotrexate response in patients with rheumatoid arthritis.Semantic proximity Read ↗

Polymorphisms and pharmacogenomics for the toxicity of methotrexate monotherapy in patients with rheumatoid arthritis: A systematic review and meta-analysis.Semantic proximity Read ↗

Pharmacogenetics of therapies in rheumatoid arthritis: An update.Semantic proximity Read ↗

Moving toward personalized medicine in rheumatoid arthritis: SNPs in methotrexate intracellular pathways are associated with methotrexate therapeutic outcome.Semantic proximity Read ↗

Pharmacogenetics of methotrexateSemantic proximity Read ↗

Pharmacogenomics of Methotrexate Membrane Transport Pathway: Can Clinical Response to Methotrexate in Rheumatoid Arthritis Be Predicted?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.